tiprankstipranks
Advertisement
Advertisement
Bayer says Kerendia met primary endpoint in Phase III FIND-CKD trial
PremiumThe FlyBayer says Kerendia met primary endpoint in Phase III FIND-CKD trial
7d ago
Bayer Targets Atrial Fibrillation With New Phase 2 Rhythm Drug: What Investors Should Watch
Premium
Company Announcements
Bayer Targets Atrial Fibrillation With New Phase 2 Rhythm Drug: What Investors Should Watch
8d ago
Bayer announces new investigational data from Kerendia’s Phase III trial
Premium
The Fly
Bayer announces new investigational data from Kerendia’s Phase III trial
10d ago
Bayer to present new data across oncology portfolio
PremiumThe FlyBayer to present new data across oncology portfolio
22d ago
Bayer announces Priority Review designation for Kerendia
Premium
The Fly
Bayer announces Priority Review designation for Kerendia
22d ago
Bayer upgraded to Buy from Hold at DZ Bank
Premium
The Fly
Bayer upgraded to Buy from Hold at DZ Bank
23d ago
Leerink cuts Regeneron to Market Perform on LAG-3 failure, Eylea erosion risk
PremiumThe FlyLeerink cuts Regeneron to Market Perform on LAG-3 failure, Eylea erosion risk
25d ago
Bayer announces presentation of new Phase II ARASEC data on NUBEQA
Premium
The Fly
Bayer announces presentation of new Phase II ARASEC data on NUBEQA
28d ago
Bayer Targets China Prostate Cancer Market With New Darolutamide Real‑World Study
Premium
Company Announcements
Bayer Targets China Prostate Cancer Market With New Darolutamide Real‑World Study
28d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100